BioSpace News Archive

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020.

SR Instruments, a leading manufacturer of purpose-built scales for hospitals, medical centers, and long-term care facilities, announced that its flagship product line, SR Scales, has expanded its number of touchless scales.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced a strategic partnership between its Early Phase Clinical Unit (EPCU) in Berlin, Germany and Clinical Trial Center (CTC) North, a full-service CRO located at the University Medical Center Hamburg-Eppendorf (UKE). The strategic collaboration support

CVS Health Corporation announced that Neela Montgomery has been named Executive Vice President and President of CVS Pharmacy/Retail, effective November 30, 2020.

Partnership will use AI to match patients with the best treatments based on their biological profiles. Work in Florida will serve as a model for the rest of the USA

AliveCor , the leader in AI-based personal ECG technology and provider of enterprise cardiology solutions, today announced that the US FDA had given clearance to the company’s next generation of interpretive ECG algorit

Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4.

Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded tri

N-803 Boosts CD34+ Progenitor-Derived NK Cell Expansion and Functionality Adding N-803 to NK Cell Therapy has Potential to Improve Cancer Immunotherapy

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Spyros Papapetropoulos, MD, PhD, to its Board of Directors. Spyros brings more than 20 years of academic and industry experience with a focus on neurology, and previously held R&D and scientific leadership roles at Acadia,